NCT05304936View on ClinicalTrials.gov

HCW9218 for Advanced Pancreatic Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

February 1, 2025

Conditions
Advanced Pancreatic Carcinoma
Interventions
DRUG

HCW9218

Bifunctional TGF-β antagonist/IL-15 protein complex

Trial Locations (5)

20892

National Institute of Health/ National Cancer Institute, Bethesda

29425

Medical University of South Carolina, Charleston

44195

Cleveland Clinic, Cleveland

63110

Washington University in St. Louis, St Louis

85258

HonorHealth, Scottsdale

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY

NCT05304936 - HCW9218 for Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter